EUVIMEDEUVIMED entdecken
Crossref

The PRMT5 inhibitor C9 mitigates hypoxia‐induced carboplatin resistance in lung cancer by inducing autophagy

Jiangjiang Fan, Haichao Li, Qiong Ruan, Ximing Zhu, Pengyu Jing, Zhongping Gu

Cell Biology International · 2023

DOI: 10.1002/cbin.12066 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Biology International, 2023. Verfasst von Jiangjiang Fan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The Second Affiliated Hospital, Air Force Medical University, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Lung Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Yin Feng Talent program of Tangdu Hospital, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypoxia, a common feature of solid tumors, can promote chemoresistance in cancer cells. PRMT5 mediates various cellular processes involved in cancer development and progression. However, the role of PRMT5 in hypoxia‐induced chemoresistance is unclear. In this study, hypoxia upregulated PRMT5 expression in lung cancer cells. Additionally, PRMT5 overexpression promoted cancer cell resistance to carboplatin. In carboplatin‐resistant cancer cells, PRMT5 overexpression promoted the methylation of ULK1, a critical regulator of autophagy. ULK1 hypermethylation leads to the upregulation of autophagy, which can improve the survival of cancer cells under hypoxic conditions. Furthermore, this study demonstrated that the PRMT5 inhibitor C9 significantly enhanced the sensitivity of lung cancer cells to carboplatin. These findings suggest that targeting PRMT5‐mediated autophagy with C9 can overcome hypoxia‐induced carboplatin resistance and improve the efficacy of chemotherapy in patients with cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsHumansCarboplatinLungHypoxiaAutophagyCell Line, TumorProtein-Arginine N-Methyltransferases

Stichwörter der Autor:innen

C9PRMT5autophagycarboplatinhypoxiaresistance

Substanzen

CarboplatinPRMT5 protein, humanProtein-Arginine N-Methyltransferases

Autor:innen und Institutionen

  • Department of Thoracic Surgery, The Second Affiliated Hospital, Air Force Medical University, Xi'an, Shaanxi, China.
  • Department of Radiology, Xi'an Affiliated Hospital of Shaanxi University of Chinese Medicine, Xi'an, Shaanxi, China.

Förderung

  • Yin Feng Talent program of Tangdu Hospital
  • National Natural Science Foundation of China

Zitieren

APA

Fan, J., Li, H., Ruan, Q., Zhu, X., Jing, P., & Gu, Z. (2023). The PRMT5 inhibitor C9 mitigates hypoxia‐induced carboplatin resistance in lung cancer by inducing autophagy. Cell Biology International. https://doi.org/10.1002/cbin.12066

Vancouver

Fan J, Li H, Ruan Q, Zhu X, Jing P, Gu Z. The PRMT5 inhibitor C9 mitigates hypoxia‐induced carboplatin resistance in lung cancer by inducing autophagy. Cell Biology International. 2023. doi:10.1002/cbin.12066

BibTeX
@article{Fan2023,
  author = {Fan, Jiangjiang and Li, Haichao and Ruan, Qiong and Zhu, Ximing and Jing, Pengyu and Gu, Zhongping},
  title = {The PRMT5 inhibitor C9 mitigates hypoxia‐induced carboplatin resistance in lung cancer by inducing autophagy},
  journal = {Cell Biology International},
  year = {2023},
  doi = {10.1002/cbin.12066}
}
Kostenlos starten →